# Halozyme Therapeutics clinical trials: 33 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials with Halozyme Therapeutics as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Halozyme Therapeutics: 33 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/halozyme-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 14, 2024 | NCT06689085 | 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With... | Halozyme Therapeutics | Phase 3 | Recruiting | Hypogonadism, Male | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06689085) |
| September 7, 2018 | NCT03662334 | A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human... | Halozyme Therapeutics | Phase 4 | Completed | Type 1 Diabetes Mellitus | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03662334) |
| August 31, 2017 | NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in... | Halozyme Therapeutics | Phase 1 | Terminated | Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03267940) |
| March 22, 2016 | NCT02715804 | A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus... | Halozyme Therapeutics | Phase 3 | Terminated | Pancreatic Ductal Carcinoma | 492 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02715804) |
| September 30, 2015 | NCT02563548 | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | Halozyme Therapeutics | Phase 1 | Completed | NSCLC, Gastric Cancer | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02563548) |
| January 27, 2015 | NCT02346370 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously... | Halozyme Therapeutics | Phase 1 | Terminated | Non-small Cell Lung Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02346370) |
| May 8, 2013 | NCT01848990 | CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in... | Halozyme Therapeutics | Phase 4 | Completed | Type 1 Diabetes Mellitus | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01848990) |
| April 25, 2013 | NCT01839487 | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated... | Halozyme Therapeutics | Phase 2 | Completed | Metastatic Pancreatic Cancer | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01839487) |
| April 5, 2012 | NCT01572012 | Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers | Halozyme Therapeutics | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01572012) |
| February 6, 2012 | NCT01526733 | Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase | Halozyme Therapeutics | Phase 4 | Completed | Type 1 Diabetes Mellitus | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01526733) |
| October 17, 2011 | NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | Halozyme Therapeutics | Phase 1/2 | Completed | Stage IV Pancreatic Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01453153) |
| January 12, 2011 | NCT01275131 | Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in... | Halozyme Therapeutics | Phase 1 | Completed | Type 1 Diabetes Mellitus | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01275131) |
| September 2, 2010 | NCT01194258 | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes... | Halozyme Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type II | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01194258) |
| September 2, 2010 | NCT01194245 | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes... | Halozyme Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type 1 | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01194245) |
| July 27, 2010 | NCT01170897 | Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors | Halozyme Therapeutics | Phase 1 | Completed | Solid Tumor | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01170897) |
| September 18, 2009 | NCT00979875 | A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone | Halozyme Therapeutics | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00979875) |
| June 26, 2009 | NCT00928447 | Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis | Halozyme Therapeutics | Phase 2 | Completed | Dermatitis, Allergic Contact | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00928447) |
| June 9, 2009 | NCT00916357 | Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to... | Halozyme Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type 2 | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00916357) |
| April 17, 2009 | NCT00883558 | Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes... | Halozyme Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type 1 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00883558) |
| March 17, 2009 | NCT00862849 | Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase... | Halozyme Therapeutics | Phase 1 | Completed | Diabetes Mellitus | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00862849) |
| February 3, 2009 | NCT00834704 | Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | Halozyme Therapeutics | Phase 1 | Completed | Solid Tumor | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00834704) |
| December 15, 2008 | NCT00807963 | Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone | Halozyme Therapeutics | Phase 1 | Completed | Risk Factors for or a Diagnosis of Osteoporosis | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00807963) |
| December 8, 2008 | NCT00803972 | Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and... | Halozyme Therapeutics | Phase 1 | Completed | Healthy Volunteers | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00803972) |
| October 31, 2008 | NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer | Halozyme Therapeutics | Phase 1 | Completed | Superficial Bladder Cancer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00782587) |
| October 17, 2008 | NCT00774800 | Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus | Halozyme Therapeutics | Phase 2 | Completed | Type 1 Diabetes Mellitus | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00774800) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 2 |
| Phase 2 | 7 |
| Phase 3 | 3 |
| Phase 4 | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 29 |
| Terminated | 3 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Insulin Resistance | 8 |
| Diabetes Mellitus, Type 1 | 7 |
| Neoplasm Metastasis | 3 |
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 2 |
| Non-Muscle Invasive Bladder Neoplasms | 2 |
| Carcinoma, Pancreatic Ductal | 2 |
| Pancreatic Neoplasms | 2 |
| Eunuchism | 1 |
| Hypogonadism | 1 |
| Pain | 1 |
| Dermatitis, Allergic Contact | 1 |
| Urinary Bladder Neoplasms | 1 |
| Arthritis, Rheumatoid | 1 |
| Dehydration | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Recurrence | 1 |
| Cholangiocarcinoma | 1 |
| Stomach Neoplasms | 1 |
| Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Children's hospitals in the United States](https://specstream.ai/data/businesses/childrens-hospitals/united-states)
- [Dialysis clinics in the United States](https://specstream.ai/data/businesses/dialysis-clinics/united-states)
- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
